Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2417

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 5
Chunk 2417
---
 $7.3 million, respectively, an increase of $1.0 million, or 13.9%. During 2024,
in connection with our Series A and Series B preferred stock conversions and the repricing of Series A Warrants, we recorded a deemed
dividend of $2.8 million. Accordingly, for the years ended December 31, 2024 and 2023, net loss attributable to common stockholders amounted
to $11.1 million, or $(19.14) per common share, and $7.3 million, or $(97.90) per common share, respectively.

Liquidity and Capital Resources

Capital Requirements

Predecessor and the Company
have not generated any revenue from any source and the Company does not expect to generate revenue for at least the next few years. If
the Company fails to complete the timely development of, or fails to obtain regulatory approval for, its product candidates, the ability
of the Company to generate future revenue will be adversely affected. The Company does not know when, or if, it will generate any revenue
from its product candidates, and does not expect to generate revenue unless and until the Company obtains regulatory approval and commercialization
of its product candidates.

The Company expects its expenses
to increase significantly in connection with its ongoing activities, particularly as it continues and expands research, preclinical development,
and clinical development to support marketing approval for its product candidates. In addition, if the Company obtains approval for any
of its product candidates, the Company expects to incur significant commercialization expenses related to sales, marketing, manufacturing
and distribution. Furthermore, the Company expects to incur additional costs associated with operating as a public company.

106

The Company, therefore, anticipates that substantial additional funding
will be needed in connection with its continuing operations. At December 31, 2024, the Company had $3.3 million in cash and cash
equivalents. The Company intends to devote most of the available cash to the preclinical and clinical development of its product candidates
and public company compliance costs. Based on current business plans, the Company believes that the cash available at December 31, 2024
will not fund its operations and capital requirements for 12 months after the filing of the audited financial statements for the year
ended December 31, 2024. The Company has arranged two equity lines of credit, one providing for the sale of up to 25,000,000 newly issued
shares of Common